Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus

Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus

Increased risk of premature cardiovascular disease in systemic lupus erythematosus (SLE) is not well understood, but in animal models, the Janus kinase inhibitor tofacitinib improves related phenotypes. Here the authors report a Phase 1 double-blind randomized trial that shows tofacitinib is safe an...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sarfaraz A. Hasni, Sarthak Gupta, Michael Davis, Elaine Poncio, Yenealem Temesgen-Oyelakin, Philip M. Carlucci, Xinghao Wang, Mohammad Naqi, Martin P. Playford, Rishi R. Goel, Xiaobai Li, Ann J. Biehl, Isabel Ochoa-Navas, Zerai Manna, Yinghui Shi, Donald Thomas, Jinguo Chen, Angélique Biancotto, Richard Apps, Foo Cheung, Yuri Kotliarov, Ashley L. Babyak, Huizhi Zhou, Rongye Shi, Katie Stagliano, Wanxia Li Tsai, Laura Vian, Nathalia Gazaniga, Valentina Giudice, Shajia Lu, Stephen R. Brooks, Meggan MacKay, Peter Gregersen, Nehal N. Mehta, Alan T. Remaley, Betty Diamond, John J. O’ Shea, Massimo Gadina, Mariana J. Kaplan
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/8b6b0cd6bcc44990af2223bf0755ce63
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:8b6b0cd6bcc44990af2223bf0755ce63
record_format dspace
spelling oai:doaj.org-article:8b6b0cd6bcc44990af2223bf0755ce632021-12-02T17:52:38ZPhase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus10.1038/s41467-021-23361-z2041-1723https://doaj.org/article/8b6b0cd6bcc44990af2223bf0755ce632021-06-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-23361-zhttps://doaj.org/toc/2041-1723Increased risk of premature cardiovascular disease in systemic lupus erythematosus (SLE) is not well understood, but in animal models, the Janus kinase inhibitor tofacitinib improves related phenotypes. Here the authors report a Phase 1 double-blind randomized trial that shows tofacitinib is safe and well tolerated in in patients with SLE.Sarfaraz A. HasniSarthak GuptaMichael DavisElaine PoncioYenealem Temesgen-OyelakinPhilip M. CarlucciXinghao WangMohammad NaqiMartin P. PlayfordRishi R. GoelXiaobai LiAnn J. BiehlIsabel Ochoa-NavasZerai MannaYinghui ShiDonald ThomasJinguo ChenAngélique BiancottoRichard AppsFoo CheungYuri KotliarovAshley L. BabyakHuizhi ZhouRongye ShiKatie StaglianoWanxia Li TsaiLaura VianNathalia GazanigaValentina GiudiceShajia LuStephen R. BrooksMeggan MacKayPeter GregersenNehal N. MehtaAlan T. RemaleyBetty DiamondJohn J. O’ SheaMassimo GadinaMariana J. KaplanNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
institution DOAJ
collection DOAJ
language EN
topic Science
Q
spellingShingle Science
Q
Sarfaraz A. Hasni
Sarthak Gupta
Michael Davis
Elaine Poncio
Yenealem Temesgen-Oyelakin
Philip M. Carlucci
Xinghao Wang
Mohammad Naqi
Martin P. Playford
Rishi R. Goel
Xiaobai Li
Ann J. Biehl
Isabel Ochoa-Navas
Zerai Manna
Yinghui Shi
Donald Thomas
Jinguo Chen
Angélique Biancotto
Richard Apps
Foo Cheung
Yuri Kotliarov
Ashley L. Babyak
Huizhi Zhou
Rongye Shi
Katie Stagliano
Wanxia Li Tsai
Laura Vian
Nathalia Gazaniga
Valentina Giudice
Shajia Lu
Stephen R. Brooks
Meggan MacKay
Peter Gregersen
Nehal N. Mehta
Alan T. Remaley
Betty Diamond
John J. O’ Shea
Massimo Gadina
Mariana J. Kaplan
Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus
description Increased risk of premature cardiovascular disease in systemic lupus erythematosus (SLE) is not well understood, but in animal models, the Janus kinase inhibitor tofacitinib improves related phenotypes. Here the authors report a Phase 1 double-blind randomized trial that shows tofacitinib is safe and well tolerated in in patients with SLE.
format article
author Sarfaraz A. Hasni
Sarthak Gupta
Michael Davis
Elaine Poncio
Yenealem Temesgen-Oyelakin
Philip M. Carlucci
Xinghao Wang
Mohammad Naqi
Martin P. Playford
Rishi R. Goel
Xiaobai Li
Ann J. Biehl
Isabel Ochoa-Navas
Zerai Manna
Yinghui Shi
Donald Thomas
Jinguo Chen
Angélique Biancotto
Richard Apps
Foo Cheung
Yuri Kotliarov
Ashley L. Babyak
Huizhi Zhou
Rongye Shi
Katie Stagliano
Wanxia Li Tsai
Laura Vian
Nathalia Gazaniga
Valentina Giudice
Shajia Lu
Stephen R. Brooks
Meggan MacKay
Peter Gregersen
Nehal N. Mehta
Alan T. Remaley
Betty Diamond
John J. O’ Shea
Massimo Gadina
Mariana J. Kaplan
author_facet Sarfaraz A. Hasni
Sarthak Gupta
Michael Davis
Elaine Poncio
Yenealem Temesgen-Oyelakin
Philip M. Carlucci
Xinghao Wang
Mohammad Naqi
Martin P. Playford
Rishi R. Goel
Xiaobai Li
Ann J. Biehl
Isabel Ochoa-Navas
Zerai Manna
Yinghui Shi
Donald Thomas
Jinguo Chen
Angélique Biancotto
Richard Apps
Foo Cheung
Yuri Kotliarov
Ashley L. Babyak
Huizhi Zhou
Rongye Shi
Katie Stagliano
Wanxia Li Tsai
Laura Vian
Nathalia Gazaniga
Valentina Giudice
Shajia Lu
Stephen R. Brooks
Meggan MacKay
Peter Gregersen
Nehal N. Mehta
Alan T. Remaley
Betty Diamond
John J. O’ Shea
Massimo Gadina
Mariana J. Kaplan
author_sort Sarfaraz A. Hasni
title Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus
title_short Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus
title_full Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus
title_fullStr Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus
title_full_unstemmed Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus
title_sort phase 1 double-blind randomized safety trial of the janus kinase inhibitor tofacitinib in systemic lupus erythematosus
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/8b6b0cd6bcc44990af2223bf0755ce63
work_keys_str_mv AT sarfarazahasni phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT sarthakgupta phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT michaeldavis phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT elaineponcio phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT yenealemtemesgenoyelakin phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT philipmcarlucci phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT xinghaowang phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT mohammadnaqi phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT martinpplayford phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT rishirgoel phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT xiaobaili phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT annjbiehl phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT isabelochoanavas phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT zeraimanna phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT yinghuishi phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT donaldthomas phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT jinguochen phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT angeliquebiancotto phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT richardapps phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT foocheung phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT yurikotliarov phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT ashleylbabyak phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT huizhizhou phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT rongyeshi phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT katiestagliano phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT wanxialitsai phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT lauravian phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT nathaliagazaniga phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT valentinagiudice phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT shajialu phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT stephenrbrooks phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT megganmackay phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT petergregersen phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT nehalnmehta phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT alantremaley phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT bettydiamond phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT johnjoshea phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT massimogadina phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
AT marianajkaplan phase1doubleblindrandomizedsafetytrialofthejanuskinaseinhibitortofacitinibinsystemiclupuserythematosus
_version_ 1718379178338811904

Ejemplares similares